Brief: Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
16/12/2021 12:37
Dec 16 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES ENTERS ANTIBODY DISCOVERY AGREEMENT WITH
TWIST
BIOSCIENCE TO DISCOVER AND DEVELOP NOVEL THERAPEUTIC ANTIBODIES
AGAINST GPCR TARGETS
Source text for Eikon: ID:nBw7wsN1ha
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up